Caen-based Datexim, the creator of a medical image analysis software, has raised $1.2 million in a Series B round. The round was led by Odyssée Venture – a French private equity firm that provides independent financial advisory services to management companies with participation from the two Company Executives. Datexim has raised a total of $2.9 million in funding over 2 rounds, Crunchbase reports.
Founded in 2011 by Jean-Hugues Pruvot and CEO Arnaud Renouf, Datexim is an innovative company specialized in medical image processing, analysis, visualization, and cytology diagnostic aid solutions, particularly for cervical cancer screening. To date, the first AI-based image analysis solution for cervical cancer screening is on the market thanks to the CE certification of CytoProcessor. Datexim is aimed to defeat cervical cancer worldwide.
The raised funds will allow them to launch new products and expand internationally. Also, the company plans to develop its infrastructure, diversify its offer, and launch solutions to help diagnose other types of cancers and diseases.
Arnaud Renouf, President of Datexim said:
“We are proud to have successfully launched our operations to laboratories which were able to quickly measure the operational benefits linked to our offer: reliability, working comfort, accuracy, and speed of diagnosis. Thanks to this fundraising, we are going to take a new one by developing our commercial and R&D strategy. We will thus accentuate our competitive advantage in order to become the global benchmark in our market.”
